Federation des caisses Desjardins du Quebec’s Aligos Therapeutics ALGS Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.06K	Buy	+950	New	+$7.21K	﹤0.01%	2415

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's ALGS Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec opened a new position in Aligos Therapeutics (ALGS) in Q1 2026: 950 shares worth $7.06K. The stake represents ﹤0.01% of the portfolio and ranks #2415 among its holdings.

35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

Federation des caisses Desjardins du Quebec held 950 shares of Aligos Therapeutics worth $7.06K as of Q1 2026.
Aligos Therapeutics was a new Federation des caisses Desjardins du Quebec position in Q1 2026.
Aligos Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2415 holding.
35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.